These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10109799)

  • 61. Benefits of clinical pharmacy services in a community hospital.
    Williams LE
    Hosp Pharm; 1993 Aug; 28(8):759-63, 766-7. PubMed ID: 10127576
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Adjusting dosage intervals of intermittent intravenous ranitidine according to creatinine clearance: a cost-minimization analysis.
    Connelly JF
    Hosp Pharm; 1994 Nov; 29(11):992, 996-8, 1001. PubMed ID: 10138581
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Reducing outpatient costs of nonsteroidal antiinflammatory drugs at a Department of Veterans Affairs teaching hospital.
    Drexler PG; Lambdin CS
    J Pharm Technol; 1993; 9(1):10-3. PubMed ID: 10123760
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Enhanced rectal absorption of cefmetazole and cefoxitin in the presence of epinephrine metabolites in rats and a high-performance liquid chromatographic assay for cephamycin antibiotics.
    Nishihata T; Takahagi H; Yamamoto M; Tomida H; Rytting JH; Higuchi T
    J Pharm Sci; 1984 Jan; 73(1):109-12. PubMed ID: 6582265
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials.
    Smith PK; Datta SK; Muhlbaier LH; Samsa G; Nadel A; Lipscomb J
    Ann Thorac Surg; 2004 Feb; 77(2):635-42; discussion 642-3. PubMed ID: 14759451
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Managing costs: a health-care imperative.
    Gouveia WA
    Am J Hosp Pharm; 1988 Jan; 45(1):90. PubMed ID: 3348236
    [No Abstract]   [Full Text] [Related]  

  • 67. Pharmacokinetics of intravenous cefmetazole with emphasis on comparison between predicted theoretical levels in tissue and actual skin window fluid levels.
    Tan JS; Salstrom SJ; Signs SA; Hoffman HE; File TM
    Antimicrob Agents Chemother; 1989 Jun; 33(6):924-7. PubMed ID: 2764542
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Model for evaluating costs associated with i.v. drug delivery systems.
    Kappeler KH; Birdwell SW; Scheckelhoff DJ; Reilly CH
    Am J Hosp Pharm; 1992 Jun; 49(6):1478-81. PubMed ID: 1529995
    [No Abstract]   [Full Text] [Related]  

  • 69. I.v. regulation device vs. infusion pump: a cost-savings study.
    Mathews JJ; Clementi P
    Nurs Manage; 1996 Nov; 27(11):32F-H. PubMed ID: 8954447
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Lessons learned from promoting a cost-effective agent.
    Husain RA; Illsley SS
    Am J Hosp Pharm; 1993 Mar; 50(3):446. PubMed ID: 8442455
    [No Abstract]   [Full Text] [Related]  

  • 71. Development and integration of cost accounting, pharmacy workload, and charging systems.
    Carlson BR
    Top Hosp Pharm Manage; 1989 Aug; 9(2):11-20. PubMed ID: 10314355
    [No Abstract]   [Full Text] [Related]  

  • 72. Evaluating the cost impact of intravenous antibiotic dosing frequencies.
    Foran RM; Brett JL; Wulf PH
    DICP; 1991 May; 25(5):546-52. PubMed ID: 2068840
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Containing cefoxitin costs through a program to curtail use in surgical prophylaxis.
    Taylor G; Blondel-Hill E; Kibsey P; Friesen E; Tisdell R; Vaudry W
    Can J Infect Dis; 1993 Sep; 4(5):275-8. PubMed ID: 22346462
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Single-blind, prospective, randomized study of cefmetazole and cefoxitin in the treatment of postcesarean endometritis.
    Chatwani A; Martens M; Grimes DA; Chatterjee M; Noah M; Stamp-Cole MM; Perry KT;
    Infect Dis Obstet Gynecol; 1995; 3(1):28-33. PubMed ID: 18475417
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A study of direct labor costs in hospital pharmacy systems using the model concept.
    Hepler CD
    Am J Hosp Pharm; 1966 Dec; 23(12):645-61. PubMed ID: 5980096
    [No Abstract]   [Full Text] [Related]  

  • 76. [Costs of a cytostatic drug preparation unit in a hospital in Mexico].
    Martínez Rodríguez OA; Rivas Bocanegra RE; Ascencio-Pérez IS; Zapata Sánchez LA
    Farm Hosp; 2007; 31(6):375-8. PubMed ID: 18348668
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cost comparisons of antimicrobial agents.
    Wyant S; Jacobs J
    Am J Hosp Pharm; 1986 Oct; 43(10):2394, 2396. PubMed ID: 3788991
    [No Abstract]   [Full Text] [Related]  

  • 78. An on-line, column-switching high-performance liquid chromatographic procedure for the removal of probenecid from human plasma, serum, or urine in the quantitative determination of cefmetazole or cefoxitin.
    Bothwell WM; Cathcart KS; Bombardt PA
    J Pharm Biomed Anal; 1989; 7(8):987-95. PubMed ID: 2490108
    [No Abstract]   [Full Text] [Related]  

  • 79. [Salivary elimination of cefoxitin after intramuscular administration in healthy volunteers].
    Pase U; Celli G
    G Stomatol Ortognatodonzia; 1986; 5(4):89-90. PubMed ID: 3482446
    [No Abstract]   [Full Text] [Related]  

  • 80. Applying Lean Techniques to Reduce Intravenous Waste Through Premixed Solutions and Increasing Production Frequency.
    Lin AC; Penm J; Ivey MF; Deng Y; Commins M
    J Healthc Qual; 2018; 40(1):2-8. PubMed ID: 27427883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.